L. Michael Glodé

4.4k total citations · 1 hit paper
71 papers, 3.4k citations indexed

About

L. Michael Glodé is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Oncology. According to data from OpenAlex, L. Michael Glodé has authored 71 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 22 papers in Immunology and 15 papers in Oncology. Recurrent topics in L. Michael Glodé's work include Prostate Cancer Treatment and Research (32 papers), Prostate Cancer Diagnosis and Treatment (19 papers) and Immunotherapy and Immune Responses (11 papers). L. Michael Glodé is often cited by papers focused on Prostate Cancer Treatment and Research (32 papers), Prostate Cancer Diagnosis and Treatment (19 papers) and Immunotherapy and Immune Responses (11 papers). L. Michael Glodé collaborates with scholars based in United States, India and Canada. L. Michael Glodé's co-authors include David L. Rosenstreich, Gail S. Harrison, Thomas W. Flaig, Rajesh Agarwal, Philip W. Kantoff, David L. Bilhartz, Frances Crighton, Thomas Schuetz, Wayne R. Godfrey and William L. Dahut and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

L. Michael Glodé

70 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations L. Michael Glodé et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Michael Glodé United States	31	1.3k	1.2k	937	924	595	71	3.4k
Lee Goodglick United States	42	1.5k 1.2×	2.6k 2.2×	889 0.9×	1.5k 1.6×	804 1.4×	98	5.5k
Raymond C. Bergan United States	43	1.2k 0.9×	2.4k 2.1×	384 0.4×	1.4k 1.6×	939 1.6×	136	5.2k
Clara Natoli Italy	34	575 0.4×	2.0k 1.7×	2.1k 2.2×	1.7k 1.8×	509 0.9×	151	4.8k
Peter J. Bugelski United States	39	563 0.4×	1.7k 1.5×	1.6k 1.7×	780 0.8×	353 0.6×	137	5.2k
Kazuma Kiyotani Japan	37	458 0.4×	1.2k 1.0×	1.1k 1.2×	2.1k 2.3×	508 0.9×	131	4.2k
Sanjay Goel United States	37	879 0.7×	1.7k 1.5×	520 0.6×	2.9k 3.2×	549 0.9×	269	5.2k
Jan H. Beumer United States	40	683 0.5×	2.3k 2.0×	417 0.4×	2.1k 2.3×	489 0.8×	234	4.8k
Hong Ren China	38	394 0.3×	1.4k 1.2×	844 0.9×	512 0.6×	515 0.9×	310	5.4k
Carlo V. Catapano Switzerland	37	550 0.4×	2.6k 2.2×	632 0.7×	1.4k 1.5×	783 1.3×	116	4.4k
L. H. Schmidt Germany	28	439 0.3×	1.3k 1.1×	358 0.4×	940 1.0×	726 1.2×	115	4.1k

Countries citing papers authored by L. Michael Glodé

Since Specialization

Citations

This map shows the geographic impact of L. Michael Glodé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Michael Glodé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Michael Glodé more than expected).

Fields of papers citing papers by L. Michael Glodé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Michael Glodé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Michael Glodé. The network helps show where L. Michael Glodé may publish in the future.

Co-authorship network of co-authors of L. Michael Glodé

This figure shows the co-authorship network connecting the top 25 collaborators of L. Michael Glodé. A scholar is included among the top collaborators of L. Michael Glodé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Michael Glodé. L. Michael Glodé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halpern, Alison L., Robert J. Torphy, Martin D. McCarter, et al.. (2019). A familial germline mutation in KIT associated with achalasia, mastocytosis and gastrointestinal stromal tumors shows response to kinase inhibitors. Cancer Genetics. 233-234. 1–6. 9 indexed citations

Kessler, Elizabeth R., Lih‐Jen Su, Dexiang Gao, et al.. (2018). Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integrative Cancer Therapies. 17(4). 1103–1108. 6 indexed citations

Schlaepfer, Isabel R., Leah Rider, Lindsey Ulkus Rodrigues, et al.. (2014). Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer. Molecular Cancer Therapeutics. 13(10). 2361–2371. 249 indexed citations

Beer, Tomasz M., Paul F. Schellhammer, John M. Corman, et al.. (2013). Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. Urology. 82(2). 410–415. 14 indexed citations

Flaig, Thomas W. & L. Michael Glodé. (2008). Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opinion on Pharmacotherapy. 9(16). 2829–2841. 20 indexed citations

Raina, Komal, Marie‐José Blouin, Rana P. Singh, et al.. (2007). Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Research. 67(22). 11083–11091. 65 indexed citations

Flaig, Thomas W., Albaha Barqawi, Gary J. Miller, et al.. (2006). A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer. Cancer. 107(2). 266–274. 45 indexed citations

Flaig, Thomas W., Daniel L. Gustafson, Lih‐Jen Su, et al.. (2006). A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs. 25(2). 139–146. 264 indexed citations

Yang, Wei‐Hsiung, et al.. (2006). A Sandwich Enzyme‐Linked Immunoabsorbent Assay for Measurement of Gonadotropin‐Releasing Hormone‐Toxin Conjugates. American Journal of Reproductive Immunology. 55(3). 208–216. 1 indexed citations

10.

Flaig, Thomas W., et al.. (2006). The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Ultrasonics. 46(1). 68–73. 12 indexed citations

11.

Harrison, Gail S., Margaret E. Wierman, Terry M. Nett, & L. Michael Glodé. (2004). Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocrine Related Cancer. 11(4). 725–748. 131 indexed citations

12.

Fung, Kim Y. C., et al.. (2004). A comprehensive characterization of the peptide and protein constituents of human seminal fluid. The Prostate. 61(2). 171–181. 117 indexed citations

13.

Skinner, Eila C. & L. Michael Glodé. (2003). High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urologic Oncology Seminars and Original Investigations. 21(3). 219–227. 15 indexed citations

14.

Tyagi, Anil K., Chapla Agarwal, Rana P. Singh, et al.. (2003). Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and Biophysical Research Communications. 312(4). 1178–1184. 54 indexed citations

15.

Mazzini, Massimo & L. Michael Glodé. (2001). INTERNET ONCOLOGY. Hematology/Oncology Clinics of North America. 15(3). 583–592. 4 indexed citations

16.

Shanafelt, Tait D., et al.. (2000). Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Molecular and Cellular Probes. 14(4). 211–217. 50 indexed citations

17.

Maxwell, Ian H., L. Michael Glodé, & F Maxwell. (1992). Expression of Diphtheria Toxin A-Chain in Mature B-Cells: A Potential Approach to Therapy of B-Lymphoid Malignancy. Leukemia & lymphoma. 7(5-6). 457–462. 17 indexed citations

18.

Mohler, James L., Leonard G. Gomella, E. David Crawford, et al.. (1992). Phase II evaluation of coumarin (1,2‐benzopyrone) in metastatic prostatic carcinoma. The Prostate. 20(2). 123–131. 84 indexed citations

19.

Kendall, Susan, Thomas L. Saunders, Long Jin, et al.. (1991). Targeted Ablation of Pituitary Gonadotropes in Transgenic Mice. Molecular Endocrinology. 5(12). 2025–2036. 94 indexed citations

20.

Manni, Andrea, Alice E. Boucher, Allan Lipton, et al.. (1987). Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer. Journal of Steroid Biochemistry. 27(1-3). 551–556. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact